*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | **Actinogen Medical Limited** |
| **ABN** | 14 086 778 476 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | **Dr Geoffrey Brooke** |
| **Date of last notice** | **4 November 2024** |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | 1. Direct<br>2. Indirect<br>3. Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | 2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary<br>3. Dalhigh Pty Ltd <Dalhigh Investments A/C> - Director and beneficiary |
| **Date of change** | 24 March 2025 |
| **No. of securities held prior to change** | 1. 14,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan.<br>1,554,039 fully paid ordinary shares<br>5,000,000 unlisted options ex @ $0.10 exp 24/3/2025<br>275,331 unlisted options ex @ $0.0375 exp 11/9/2026<br>501,689 unlisted options ex @ $0.05 exp 31/5/2027<br>2. 4,468,033 fully paid ordinary shares.<br>237,029 unlisted options ex @ $0.0375 exp 11/9/2026<br>87,543 unlisted options ex @ $0.05 exp 31/5/2027<br>3. 1,250,001 listed options ex @ $0.05 exp 30/9/2027 |
| **Class** | Fully paid ordinary shares<br>Unlisted options ex @ $0.10 exp 24/3/2025 |
| **Number acquired** | 1. 8,000,000 fully paid ordinary shares |
| **Number disposed** | 1. 5,000,000 unlisted options ex @ $0.10 exp 24/3/2025 |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Value/Consideration includes brokerage/gst**<br>Note: If consideration is non-cash, provide details and estimated valuation | Deemed issue price of $0.0425 per share issued pursuant to Employee Share Plan. |
| **No. of securities held after change** | 1. 22,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan.<br>1,554,039 fully paid ordinary shares<br>275,331 unlisted options ex @ $0.0375 exp 11/9/2026<br>501,689 unlisted options ex @ $0.05 exp 31/5/2027<br>2. 4,468,033 fully paid ordinary shares.<br>237,029 unlisted options ex @ $0.0375 exp 11/9/2026<br>87,543 unlisted options ex @ $0.05 exp 31/5/2027<br>1,250,001 listed options ex @ $0.05 exp 30/9/2027 |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of shares pursuant to the Employee Share Plan as approved by shareholders at the General Meeting held on 14 March 2025. Unlisted options ex @ $0.10 expiring 24/3/2025. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | N/A |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | **Actinogen Medical Limited** |
| **ABN** | 14 086 778 476 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | **Dr Steven Gourlay** |
| **Date of last notice** | **4 November 2024** |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | 1. Direct<br>2. Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | 2. SG Gourlay Nominees Pty Ltd <SG Gourlay Family A/C> - Director of trustee and beneficiary of trust |
| **Date of change** | 24 March 2025 |
| **No. of securities held prior to change** | 1. 68,362,300 fully paid ordinary shares issued pursuant to Employee Share Plan.<br>41,003,941 fully paid ordinary shares.<br>702,864 unlisted options ex @ $0.0375 exp 11/9/2026<br>1,757,440 unlisted options ex @ $0.05 exp 31/5/2027<br>25,000,000 listed options ex $0.05 exp 30/9/2027<br>2. 20,561,907 fully paid ordinary shares.<br>1,739,783 unlisted options ex @ $0.0375 exp 11/9/2026<br>642,560 unlisted options ex @ $0.05 exp 31/5/2027 |
| **Class** | Fully paid ordinary shares |
| **Number acquired** | 1. 21,000,000 fully paid ordinary shares |
| **Number disposed** | - |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Value/Consideration includes brokerage/gst**<br>Note: If consideration is non-cash, provide details and estimated valuation | Deemed issue price of $0.0425 per share pursuant to Employee Share Plan. |
| **No. of securities held after change** | 1. 89,362,300 fully paid ordinary shares issued pursuant to Employee Share Plan.<br>41,003,941 fully paid ordinary shares.<br>702,864 unlisted options ex @ $0.0375 exp 11/9/2026<br>1,757,440 unlisted options ex @ $0.05 exp 31/5/2027<br>25,000,000 listed options ex $0.05 exp 30/9/2027<br>2. 20,561,907 fully paid ordinary shares.<br>1,739,783 unlisted options ex @ $0.0375 exp 11/9/2026<br>642,560 unlisted options ex @ $0.05 exp 31/5/2027 |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of shares pursuant to the Employee Share Plan as approved by shareholders at the General Meeting held on 14 March 2025. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | N/A |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | **Actinogen Medical Limited** |
| **ABN** | 14 086 778 476 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | **Dr George Morstyn** |
| **Date of last notice** | **4 November 2024** |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | 1. Direct<br>2. Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | 2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary |
| **Date of change** | 24 March 2025 |
| **No. of securities held prior to change** | 1. 2,843,289 fully paid ordinary shares<br>5,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan.<br>299,805 unlisted options ex @ $0.0375 exp 11/9/2026<br>260,728 unlisted options ex @ $0.05 exp 31/5/2027<br>2. 5,300,174 fully paid ordinary shares.<br>307,269 unlisted options ex @ $0.0375 exp 11/9/2026.<br>113,485 unlisted options ex @ $0.05 exp 31/5/2027<br>1,250,001 listed options ex $0.05 exp 30/9/2027 |
| **Class** | Fully paid ordinary shares |
| **Number acquired** | 1. 2,000,000 fully paid ordinary shares |
| **Number disposed** | - |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Value/Consideration includes brokerage/gst**<br>Note: If consideration is non-cash, provide details and estimated valuation | Deemed issue price of $0.0425 per share pursuant to Employee Share Plan. |
| **No. of securities held after change** | 1. 2,843,289 fully paid ordinary shares<br>7,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan.<br>299,805 unlisted options ex @ $0.0375 exp 11/9/2026<br>260,728 unlisted options ex @ $0.05 exp 31/5/2027<br>2. 5,300,174 fully paid ordinary shares.<br>307,269 unlisted options ex @ $0.0375 exp 11/9/2026.<br>113,485 unlisted options ex @ $0.05 exp 31/5/2027<br>1,250,001 listed options ex $0.05 exp 30/9/2027 |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of shares pursuant to the Employee Share Plan as approved by shareholders at the General Meeting held on 14 March 2025. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | N/A |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | **Actinogen Medical Limited** |
| **ABN** | 14 086 778 476 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | **Mr Malcolm McComas** |
| **Date of last notice** | **4 November 2024** |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | 1. Direct<br>2. Indirect<br>3. Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | 2. Bunyula Super Pty Ltd <Bunyula Super Fund A/C> - director related entity and contingent beneficial interest<br>3. McComas Capital Pty Ltd <McComas Family A/C> - controller of trustee & a beneficiary of the trust<br>4. Speech Dynamics Pty Ltd – director related entity |
| **Date of change** | 24 March 2025 |
| **No. of securities held prior to change** | 1. 4,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan<br>300,000 fully paid ordinary shares<br>150,000 unlisted options ex @ $0.05 exp 31/5/2027<br>2. 1,070,219 fully paid ordinary shares<br>90,554 unlisted options ex @ $0.0375 exp 11/9/2026<br>33,445 unlisted options ex @ $0.05 exp 31/5/2027<br>3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan<br>301,617 fully paid ordinary shares<br>110,133 unlisted options ex @ $0.0375 exp 11/9/2026<br>40,676 unlisted options ex @ $0.05 exp 31/5/2027<br>4. 1,000,000 fully paid ordinary shares<br>750,000 listed options ex $0.05 exp 30/9/2027 |
| **Class** | Fully paid ordinary shares |
| **Number acquired** | 1. 2,000,000 fully paid ordinary shares |
| **Number disposed** | - |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Value/Consideration includes brokerage/gst**<br>Note: If consideration is non-cash, provide details and estimated valuation | Deemed issue price of $0.0425 per share pursuant to Employee Share Plan. |
| **No. of securities held after change** | 1. 6,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan<br>300,000 fully paid ordinary shares<br>150,000 unlisted options ex @ $0.05 exp 31/5/2027<br>2. 1,070,219 fully paid ordinary shares<br>90,554 unlisted options ex @ $0.0375 exp 11/9/2026<br>33,445 unlisted options ex @ $0.05 exp 31/5/2027<br>3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan<br>301,617 fully paid ordinary shares<br>110,133 unlisted options ex @ $0.0375 exp 11/9/2026<br>40,676 unlisted options ex @ $0.05 exp 31/5/2027<br>4. 1,000,000 fully paid ordinary shares<br>750,000 listed options ex $0.05 exp 30/9/2027 |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of shares pursuant to the Employee Share Plan as approved by shareholders at the General Meeting held on 14 March 2025. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | N/A |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | **Actinogen Medical Limited** |
| **ABN** | 14 086 778 476 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | **Dr Nicki Vasquez** |
| **Date of last notice** | **7 June 2024** |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| **Date of change** | 24 March 2025 |
| **No. of securities held prior to change** | 5,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan<br>366,667 fully paid ordinary shares<br>183,334 unlisted options ex @ $0.05 exp 31/5/2027 |
| **Class** | Fully paid ordinary shares |
| **Number acquired** | 2,000,000 fully paid ordinary shares |
| **Number disposed** | - |
| **Value/Consideration includes brokerage/gst**<br>Note: If consideration is non-cash, provide details and estimated valuation | Deemed issue price of $0.0425 per share pursuant to Employee Share Plan. |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **No. of securities held after change** | 7,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan<br>366,667 fully paid ordinary shares<br>183,334 unlisted options ex @ $0.05 exp 31/5/2027 |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of shares pursuant to the Employee Share Plan as approved by shareholders at the General Meeting held on 14 March 2025. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | N/A |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.